$12.48
4.79% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
IL0011407140
Symbol
URGN
Sector
Industry

UroGen Pharma Ltd. Stock price

$12.48
+0.38 3.14% 1M
-0.76 5.74% 6M
-2.52 16.80% YTD
-0.30 2.35% 1Y
-0.28 2.19% 3Y
-18.31 59.47% 5Y
-1.50 10.73% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.57 4.79%
ISIN
IL0011407140
Symbol
URGN
Sector
Industry

Key metrics

Market capitalization $526.65m
Enterprise Value $398.75m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.46
P/S ratio (TTM) P/S ratio 5.89
P/B ratio (TTM) P/B ratio 20.64
Revenue growth (TTM) Revenue growth 15.64%
Revenue (TTM) Revenue $89.36m
EBIT (operating result TTM) EBIT $-83.73m
Free Cash Flow (TTM) Free Cash Flow $-95.37m
Cash position $250.65m
EPS (TTM) EPS $-3.14
P/E forward negative
P/S forward 5.73
EV/Sales forward 4.34
Short interest 16.04%
Show more

Is UroGen Pharma Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

UroGen Pharma Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a UroGen Pharma Ltd. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a UroGen Pharma Ltd. forecast:

Buy
86%
Hold
14%

Financial data from UroGen Pharma Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
89 89
16% 16%
100%
- Direct Costs 8.70 8.70
7% 7%
10%
81 81
19% 19%
90%
- Selling and Administrative Expenses 110 110
24% 24%
123%
- Research and Development Expense 54 54
10% 10%
60%
-82 -82
19% 19%
-92%
- Depreciation and Amortization 1.30 1.30
25% 25%
1%
EBIT (Operating Income) EBIT -84 -84
18% 18%
-94%
Net Profit -115 -115
10% 10%
-129%

In millions USD.

Don't miss a Thing! We will send you all news about UroGen Pharma Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

UroGen Pharma Ltd. Stock News

Positive
Seeking Alpha
10 days ago
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks from the past week, aiming to spark ideas and discussions among retail investors. Veradigm Inc. is undervalued due to regulatory pressures, but has significant upside potential with strategic buyers potentially paying mid- or high-teens per share. Casey's General Stores has outperformed its peers and the S&P 500 due to its stra...
Positive
Seeking Alpha
13 days ago
Urogen's UGN-102 for bladder cancer presents a $5 billion market opportunity, prompting a continued "Strong Buy" rating despite past misjudgments. FDA approval by 06/2025 is crucial, with UGN-102 potentially being the first FDA-approved treatment for low-grade intermediate-risk NMIBC. Urogen's financials show a cash runway of over 2 years, with additional borrowing contingent on timely FDA appr...
Neutral
Seeking Alpha
20 days ago
UroGen Pharma Ltd. (NASDAQ:URGN ) Q3 2024 Earnings Call Transcript November 6, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Liz Barrett - President and CEO Mark Schoenberg - CMO David Lin - CCO Chris Degnan - CFO Conference Call Participants Tara Bancroft - TD Cowen Ram Selvaraju - H.
More UroGen Pharma Ltd. News

Company Profile

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology. Its pipeline includes upper tract urothelial carcinoma, low grade non muscle invasive bladder cancer, carcinoma in situ of the bladder, and overactive bladder. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Head office Israel
CEO Elizabeth Barrett
Employees 201
Founded 2004
Website www.urogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today